Trillium Therapeutics NASDAQ:TRIL Trillium is an immuno-oncology company developing innovative therapies for the treatment of cancer. The company’s two clinical programs, TTI-621 and TTI-622, target CD47, a “don’t eat me” signal that cancer cells frequently use to evade the immune system.

Location: | Website: www.trilliumtherapeutics.com | Industry: Biological Product (except Diagnostic) Manufacturing | Sector: Manufacturing